BioTelemetry (NASDAQ:BEAT) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday.

Several other analysts have also recently commented on BEAT. Zacks Investment Research cut BioTelemetry from a “hold” rating to a “sell” rating in a report on Thursday, February 8th. Raymond James Financial assumed coverage on BioTelemetry in a report on Thursday, October 26th. They issued an “outperform” rating and a $37.00 price target on the stock. Dougherty & Co reiterated a “buy” rating and issued a $40.00 price target on shares of BioTelemetry in a report on Wednesday, November 8th. Finally, SunTrust Banks assumed coverage on BioTelemetry in a report on Monday, October 23rd. They issued a “buy” rating and a $41.00 price target on the stock. Two analysts have rated the stock with a sell rating and seven have issued a buy rating to the stock. BioTelemetry presently has a consensus rating of “Buy” and a consensus target price of $42.86.

Shares of BioTelemetry (NASDAQ BEAT) opened at $32.95 on Wednesday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.48 and a current ratio of 1.60. The company has a market capitalization of $1,050.00, a price-to-earnings ratio of 25.15, a PEG ratio of 1.41 and a beta of 0.67. BioTelemetry has a 1-year low of $23.30 and a 1-year high of $39.20.

A number of institutional investors have recently bought and sold shares of the stock. Millrace Asset Group Inc. boosted its holdings in BioTelemetry by 103.9% in the fourth quarter. Millrace Asset Group Inc. now owns 80,664 shares of the medical research company’s stock valued at $2,411,000 after acquiring an additional 41,100 shares during the last quarter. Kennedy Capital Management Inc. boosted its holdings in BioTelemetry by 26.7% in the fourth quarter. Kennedy Capital Management Inc. now owns 141,247 shares of the medical research company’s stock valued at $4,223,000 after acquiring an additional 29,741 shares during the last quarter. Landscape Capital Management L.L.C. bought a new position in BioTelemetry in the fourth quarter valued at about $248,000. Geode Capital Management LLC boosted its holdings in BioTelemetry by 4.8% in the fourth quarter. Geode Capital Management LLC now owns 273,949 shares of the medical research company’s stock valued at $8,191,000 after acquiring an additional 12,502 shares during the last quarter. Finally, Allianz Asset Management GmbH boosted its holdings in BioTelemetry by 23.1% in the fourth quarter. Allianz Asset Management GmbH now owns 526,211 shares of the medical research company’s stock valued at $15,734,000 after acquiring an additional 98,752 shares during the last quarter. Institutional investors and hedge funds own 83.27% of the company’s stock.

WARNING: This report was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://theolympiareport.com/2018/02/14/biotelemetry-beat-lifted-to-buy-at-bidaskclub.html.

BioTelemetry Company Profile

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Analyst Recommendations for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.